Cellectis to Report First Quarter 2022 Financial Results
05 Mai 2022 - 10:40PM
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS),
a clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies, today announced that it will report financial results
for the first quarter ended March 31st, 2022, on Thursday, May
12th, 2022, after the close of the US market.
The announcement will be followed by a
conference call and live audio webcast on Friday, May 13th, 2022,
at 8:00 AM EDT / 2:00 PM CET. The call will include the Company’s
first quarter results and an update on business activities. Details
for the call are as follows:Dial In Information: Friday,
May 13th, 8:00
AM EDT / 2:00 PM CET
|
Domestic: |
1-877-451-6152 |
International: |
1-201-389-0879 |
Conference ID: |
13728396 |
Webcast link: |
https://viavid.webcasts.com/starthere.jsp?ei=1539526&tp_key=3126715663 |
About Cellectis Cellectis
is a clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies. Cellectis utilizes an allogeneic approach for CAR-T
immunotherapies in oncology, pioneering the concept of
off-the-shelf and ready-to-use gene-edited CAR T-cells to treat
cancer patients, and a platform to make therapeutic gene editing in
hemopoietic stem cells for various diseases. As a clinical-stage
biopharmaceutical company with over 22 years of expertise in gene
editing, Cellectis is developing life-changing product candidates
utilizing TALEN®, its gene editing technology, and PulseAgile, its
pioneering electroporation system to harness the power of the
immune system in order to treat diseases with unmet medical needs.
Cellectis’ headquarters are in Paris, France, with locations in New
York, New York and Raleigh, North Carolina. Cellectis is listed on
the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth
(ticker: ALCLS).
For more information, visit
www.cellectis.comFollow Cellectis on social media: @cellectis,
LinkedIn and YouTube
For further information, please
contact:
Media contacts: Pascalyne
Wilson, Director, Communications, +33 (0)7 76 99 14 33,
media@cellectis.com Margaret Gandolfo, Senior Manager,
Communications, +1 (646) 628 0300
Investor Relation
contact: Arthur Stril, Chief Business Officer, +1
(347) 809 5980, investors@cellectis.com Ashley R.
Robinson, LifeSci Advisors, +1 617 430
7577 Forward-looking Statements
This press release contains “forward-looking” statements within the
meaning of applicable securities laws, including the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by words such as “anticipate,”
“believe,” “intend”, “expect,” “plan,” “scheduled,” “could” and
“will,” or the negative of these and similar expressions. These
forward-looking statements, which are based on our management’s
current expectations and assumptions and on information currently
available to management. Forward-looking statements include
statements about the meaning of the preclinical results of our
product candidates and the resulting outcome on our clinical
results. These forward-looking statements are made in light of
information currently available to us and are subject to numerous
risks and uncertainties, including with respect to the numerous
risks associated with biopharmaceutical product candidate
development. With respect to our cash runway, our operating plans,
including product development plans, may change as a result of
various factors, including factors currently unknown to us.
Furthermore, many other important factors, including those
described in our Annual Report on Form 20-F and the financial
report (including the management report) for the year ended
December 31, 2021 and subsequent filings Cellectis makes with the
Securities Exchange Commission from time to time, as well as other
known and unknown risks and uncertainties may adversely affect such
forward-looking statements and cause our actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
- Q1_EarningsCall_Announcement
Cellectis Nom Eo 05 (EU:ALCLS)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Cellectis Nom Eo 05 (EU:ALCLS)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024